Digital Look

Welcome to Digital Look++,
you are not logged in

Immupharma (IMM)

Pharma and Biotech

2.17p

	£ (Millions)	£ (Millions)
Cash Flow Statement	31-Dec-10	31-Dec-09

Net Cash Flow From Operating Activities	(6.85)	11.96
ROI, Servicing of Finance
Assocs/JV Dividends Received	_bn/a	_bn/a
Interests & Other Dividends Received	n/a	n/a
Interest Paid	_bn/a	_bn/a
Minorities & Non-Equity Divs Paid	_bn/a	_bn/a
	n/a	n/a

Taxation Paid	_bn/a	_bn/a

Gross Cash Flow	_bn/a	_bn/a

Capital Expd & Financial Inv
Interests & Other Dividends Received	0.01	0.06
Disposal of Property, Plant & Equipment	n/a	n/a
Disposal of Investments	n/a	n/a
Purchase of Property, Plant & Equipment	(0.08)	n/a
Purchase of Investments	n/a	n/a
Net Purchase of Intangible Assets	n/a	n/a
Other Investing Cash Flow	n/a	n/a
	(0.07)	0.06
Financing Activities
Dividends Paid	n/a	n/a
Repayments of Borrowings	(0.03)	(0.30)
Borrowings	0.40	0.01
Other Financing Cash Flow	0.19	0.15
	0.56	(0.14)
Net Increase/Decrease In Cash	(6.36)	11.88

Key Financials	31-Dec-10	31-Dec-09

Shares in Issue - Year End	81.53	81.09

Financial Data
Cash Incr/Decr per Share	(7.83p)	15.33p
Operating Cash Flow per Share	(8.43p)	15.44p
Gross Cash Flow per Share	_bn/a	_bn/a

Market Data
Price/Operating Cash Flow	(10.3)	6.2

* GAAP

a. Operating activities before tax

b. Not disclosed under IFRS

c. Not previously included in financing activities

d. Based on operating cash flow before tax

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: Forecast figures based on normalised accounts.